Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10139332 | 1.00 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12776325 | 1.00 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22260376 | 0.82 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19217960 | 0.82 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL682768 | 0.82 | CA12 (0.58) | CA12CA1CA2CA7CA9 | |
| Ammonia Solution, Strong SCHEMBL7992450 | 0.80 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8785084 | 0.79 | CA12 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL25482195 | 0.79 | KDM4E (0.41) | HTTHTR2A | |
| SCHEMBL4188000 | 0.78 | CYP2D6 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4172951 | 0.78 | CYP2D6 (0.59) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9725419-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | MIDCAP FINANCIAL TRUST | 2016-01-28 | — | — | US | disclosed |
| US-9096542-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130210814-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8410093-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-7858633-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7754714-B2 | (1S, 2R)-N4-(2-Aminocarbonylcyclopent-1-yl)-5-fluoro-N2-[4-(4-methylpiperazin-1-yl)-3-methylphenyl]-2,4-pyrimidinediamine, having antiproliferative activity, used to inhibit cellular proliferation and to treat proliferate diseases such as cancers | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080009494-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | CA12 4821/4885CA1 4879/4885CA2 4730/4885 |
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | CA12 4611/4885CA1 4686/4885CA2 3477/4885 |
| US-20080009494-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | CA12 4821/4885CA1 4879/4885CA2 4730/4885 |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | CA12 4611/4885CA1 4686/4885CA2 3477/4885 |
| US-20130210814-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | CA12 4821/4885CA1 4879/4885CA2 4730/4885 |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | CA12 4360/4885CA1 4194/4885CA2 1279/4885 |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | CA12 4611/4885CA1 4686/4885CA2 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.